Steven R. Deitcher, MD, was appointed President and Chief Executive Officer and a member of the Board of Directors for Talon Therapeutics in August 2007. Dr. Deitcher originally joined Talon as Executive Vice President of Development and Chief Medical Officer in May 2007. From 2004 until he joined Talon, Dr. Deitcher served as Vice President, Chief Medical Scientist at Nuvelo where he was responsible for clinical development and medical affairs. Dr. Deitcher has more than 15 years of experience as a practicing physician in hematology, medical oncology and vascular medicine. Dr. Deitcher was formerly the head of the section of hematology and coagulation medicine in the department of hematology/oncology and director of research in the department of vascular medicine at The Cleveland Clinic Foundation. While at The Cleveland Clinic, Dr. Deitcher was hematology medical director for the Network for Oncology Communication and Research. Prior to that, he spent four years at The University of Tennessee in positions including associate chairman, department of medicine; director, combined pediatric and adult thrombosis clinic; and director, special coagulation laboratory. Dr. Deitcher earned his B.S. and M.D. in the Honors Program in Medical Education at Northwestern University Medical School. He completed his residency in internal medicine at Barnes Hospital and completed his fellowship training in hematology and medical oncology at New England Medical Center and Tufts University School of Medicine. Dr. Deitcher is a member of several medical societies, including The American Society of Hematology, American Society of Clinical Oncology and the International Society on Thrombosis and Hemostasis, and is a fellow of the Society for Vascular Medicine and Biology. He has published more than 185 journal papers, abstracts and book chapters and has made more than 35 scientific conference presentations. He was the founding editor-in-chief of the journal Current Hematology Reports.

Craig Carlson joined Talon Therapeutics as Vice President in March 2010 and was appointed Chief Financial Officer in April 2010. He is responsible for all finance, accounting and administrative functions of the Company. Most recently, Mr. Carlson served as Chief Financial Officer and Chief Operating Officer for a new business incubator focused primarily on applying life science technologies to high value niche opportunities worldwide, where he was responsible for managing several businesses, including four international subsidiaries. From 2006 to 2008, he was Chief Financial Officer of Neurobiological Technologies, Inc. and from 1993 to 2005 Mr. Carlson served as Chief Financial Officer and Chief Operating Officer of Cygnus, Inc. Mr. Carlson received his M.B.A. from the Stanford Graduate School of Business, his M.S. Ed. from Hofstra University, and his B.A. in Political Science from Union College in Schenectady, N.Y.

Anne E. Hagey, MD joined Talon Therapeutics in April 2008 and is responsible for all aspects of pre-clinical and clinical development for Talon's portfolio of cancer therapeutic and supportive care candidates. Before becoming a Global Project Head, Dr. Hagey held various positions at Abbott Laboratories working on drug transition, Phase 1 and Phase 2 oncology programs. This included a fellowship for physicians at Abbott that encompassed all aspects of drug development including discovery, safety and clinical studies. Dr. Hagey has a faculty appointment at the University of Chicago, Department of Pediatrics section of Hematology-Oncology. She conducted her fellowship at University of California, Los Angeles in the Department of Microbiology and Molecular Genetics and the Department of Pediatric Hematology-Oncology and Bone Marrow Transplant. Dr. Hagey did her residency at Baylor College of Medicine, Texas Children's Hospital. Dr. Hagey earned a Doctor of Medicine from Loyola University Chicago Stritch School of Medicine and a Bachelor of Sciences.

Gradon D. Knotts joined Talon Therapeutics in May 2008 as Vice President, Business Development and brings over 20 years of pharmaceutical/biotech experience to the company including successfully negotiating more than 15 business development transactions. Prior to joining Talon, Mr. Knotts was Vice President, Business and Corporate Development at Sunesis Pharmaceuticals where, as a member of their executive committee, he was responsible for product and technology in- and out-licensing and strategic marketing. In addition to being responsible for the development and implementation of the company's partnering strategy, he played a central role in the creation and management of Sunesis' internal portfolio review and prioritization process. Prior to Sunesis, Mr. Knotts served as Senior Director, Business Development for Xenogen Corporation where he set strategy and negotiated several business development deals for Xenogen's biophotonic imaging product line. Mr. Knotts also held positions of increasing responsibility at Roche Bioscience and Syntex Corporation, in the areas of global strategic marketing, business development, managed healthcare contracts, market research/analysis and financial analysis. Mr. Knotts holds an M.B.A. from the University of Notre Dame with concentrations in Finance and Management and a B.S. degree in Finance from Brigham Young University.

Dr. Messerschmidt has >20 years of Industry experience. He joined Talon Therapeutics in January 2010 as Executive Director of Clinical Research and was subsequently promoted to Vice President, Clinical Research. His major focus has been the closure of the 407 registration trial and the Co-Lead of the NDA filing. Prior to Talon, Dr. Messerschmidt has held senior positions at Onyx Pharmaceuticals, ICON Clinical Research, Chairman of Wild-Type Enterprises (a Clinical Oncology Consulting Co.), Kimeragen, Inc, CR Bard, DNX Corp, and CIBA-Geigy Pharmaceuticals. Preceding joining the industry, Dr. Messerschmidt trained in Hematology and Medical Oncology at the National Cancer Institute, NIH, Bethesda, Maryland and held several academic appointments.

Nandan Oza joined Talon Therapeutics in August 2010 as Vice President, Chemistry, Manufacturing and Controls (CMC). Mr. Oza was last employed at Jazz Pharmaceuticals as VP, Manufacturing and Supply Chain Operations. Prior to that, he was VP, Manufacturing and Supply Chain Operations at Connetics Corporation (now GSK). Mr. Oza also held positions of increasing responsibility at ALZA Pharmaceuticals (now Johnson and Johnson) in product Development, Quality and Technical and Manufacturing Operations. His last position at ALZA was as Executive Director, Bay Area Operations. Mr. Oza earned a Bachelor's degree (with honors) in Mechanical Engineering from the University of Houston, did graduate studies in Engineering from the University of California, Davis and earned an MBA from National University, San Diego, CA.

Thomas J. Tarlow joined Talon Therapeutics in January 2009 and is responsible for the development and implementation of regulatory strategies and quality systems as well as managing all U.S. and foreign regulatory filings for the Company's pipeline of dose-intensifying and compliance-enhancing oncology product candidates. Prior to joining Talon, Mr. Tarlow served as Vice President, Regulatory Affairs at Tercica, Inc., where he planned, directed, and implemented global regulatory activities. Previously, he held various senior positions at Amgen, Inc., SUGEN, Inc. and ALZA Corporation. While at ALZA, Mr. Tarlow led regulatory support for its liposomal formulation technology platforms and achieved U.S. FDA priority approval of DOXIL® for treatment of advanced ovarian cancer. Mr. Tarlow received his MS in Comparative Pathology from University of California, Davis, School of Veterinary Medicine and his AB in Biology from University of California, Santa Cruz.

Chief of the Division of Hematologic Neoplasia, Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, and Vice Chair of the Joint Program in Transfusion Medicine, Dana-Farber Cancer Institute; Kraft Family Professor of Medicine, Harvard Medical School

Kenneth C. Anderson, M.D. – Scientific Advisory Board Member. Dr. Anderson graduated from John Hopkins Medical School, trained in internal medicine at John Hopkins' Hospital, and completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. He is the Kraft Family Professor of Medicine at Harvard Medical School; and serves as Chief of Division of Hematologic Neoplasia, Director of the Jerome Lipper Multiple Myeloma Center, and Vice Chair of the Joint Program in Transfusion Medicine at Dana-Farber Cancer Institute. He serves as chair of the NCCN Multiple Myeloma Clinical Practice Guidelines Committee; as a Cancer and Leukemia Group B Principal Investigator; on the Board of Scientific Advisors of the International Myeloma Foundation; as well as on the Board of Directors and Chair of the Leadership Committee of the Multiple Myeloma Research Consortium.

Professor of Medicine, Cleveland Clinic Foundation (CCF) Lerner College of Medicine of Case Western Reserve University; Emeritus Staff Consultant, CCF Taussig Cancer Center; Chairman Medical Advisory Committee, Kidney Cancer Association

Professor of Medicine; Head of Hematology and Director of Hematology Research, Georgetown University Hospital; Chairman of the Lymphoma Committee of the Cancer and Leukemia Group B; Co-chair of the International Harmonization Project in Lymphoma and the AJCC Subcommittee on Lymphoma; President-Elect and Scientific Advisory Board Member of the Lymphoma Research

Bruce D. Cheson, M.D., FACP, FAAS – Scientific Advisory Board Member. Dr. Cheson attended the University of Virginia and then Tufts University Medical School. He completed his internship and residency in Internal Medicine at the University of Virginia Hospitals and then a clinical and research fellowship in Hematology at New England Medical Center Hospital. From 1977-1984 he was Assistant Professor of Medicine in the Division of Hematology/Oncology at the University of Utah. From 1986-2002, he was Head, Medicine Section, CTEP at the National Cancer Institute. Since 2002, Dr. Cheson has been Professor of Medicine, Head of Hematology and Director of Hematology Research at Georgetown University Hospital. Dr. Cheson has authored over 300 medical publications and abstracts and has contributed to over 50 texts. He is on the editorial board of numerous journals and is Associate Editor of the Journal of Clinical Oncology, Oncology, and Oncology News international. He is an Editor-in-Chief of Clinical Lymphoma and Myeloma and Clinical Advances in Hematology and Oncology. He has also been the editor of the American College of Physician's Medical Knowledge Assessment Program in Oncology and the ASCO SEP. He has served on several committees of the American Society of Clinical Oncology and was on its Board of Directors, and edited ASCO News and ASCO Daily News. From 2002-2006, he was on the Oncologic Drug Advisory Committee to the U.S. Food and Drug Administration. He currently chairs the Lymphoma Committee of the Cancer and Leukemia Group B, and is co-chair of the International Harmonization Project in Lymphoma and the AJCC Subcommittee on Lymphoma. He is on the Scientific Advisory Board of the Lymphoma Research Foundation and is its President-Elect. Dr. Cheson's clinical interests focus on the development and evaluation of new therapeutic approaches for hematologic malignancies.

Founding Scientific Director, Centre for Drug Research and Development; Professor, Department of Biochemistry and Molecular Biology, University of British Columbia

Professor of Medicine and Internist; Chair of the Department of Leukemia, University of Texas M.D. Anderson Cancer Center

Hagop M. Kantarjian, M.D. – Scientific Advisory Board Member. Dr. Kantarjian is Professor and Chairman of University of Texas M. D. Anderson Cancer Center. He received his M.D. in 1979 from American University of Beirut, Beirut, Lebanon and completed his internship and residency at University of Beirut, Beirut, Lebanon in 1980. In addition, he received his Internal Medicine Degree in 1981 from American University of Beirut, Beirut, Lebanon and his Medical Oncology Subspecialty Degree in 1983 from Anderson Cancer Center, Houston, Texas. He has authored more than 700 peer-reviewed publications and 90 book chapters. In 2005, he was nominated as "America's Top Doctors", Castle Connolly Medical, 5th Edition, National Guide, Southwestern Region, Top Hematologist.

Director, Yale Cancer Center; Physician-in-Chief of Smilow Cancer Hospital at Yale-New Haven

Thomas Lynch, Jr., M.D. – Scientific Advisory Board Member. Dr. Lynch is the Director of Yale Cancer Center and the Physician-in-Chief of Smilow Cancer Hospital at Yale-New Haven. Prior to his appointment to Yale, Dr. Lynch was an associate professor of medicine at Harvard Medical School and director of the Oncology Service Line at Dana-Farber Partners CancerCare. He received his M.D. in 1986 from Yale University and completed his internship and residency at MGH in 1989. Dr. Lynch served as a fellow in medical oncology at the Dana-Farber Cancer Institute from 1989-1991 and joined the Kenneth B. Schwartz Center in 1996, becoming Medical Director in 2000. In 2002 he assumed responsibility for the direction of the Oncology Service Line at Partners Healthcare. As director of the MGH Thoracic Oncology Center, Dr. Lynch worked with advanced fellows in thoracic oncology, leading to important contributions in developmental therapeutics, molecular epidemiology, and clinical economics. He is the author of numerous publications and maintains a vigorous clinical practice.

Professor of Medicine; Vice President for Clinical Research; Chairman, Department of Gynecologic Medical Oncology, University of Texas M.D. Anderson Cancer Center